Clinical outcomes of incident peritoneal dialysis patients coming from kidney transplantation program: A case-control study

Laurisson Albuquerque da Costa, Maria Cláudia Cruz Andreoli, Aluizio Barbosa Carvalho, Sérgio Antonio Draibe, José Osmar Medina Pestana, Maria Eugênia Fernandes Canziani*

Department of Internal Medicine, Division of Nephrology, Federal University of São Paulo, São Paulo, Brazil

* mecanziani1@gmail.com

Abstract

Introduction

Brazil ranks second in the absolute number of transplantations in the world. Despite improvements in graft survival, many patients will progress to graft loss and return to dialysis. Concerns exist regarding adverse clinical outcomes in this population when undergoing peritoneal dialysis (PD).

Objective

To compare the occurrence of mortality, technique failure, and peritonitis among incident patients in PD coming from either Tx or predialysis treatment.

Methodology

A retrospective study in which 47 adult patients with Tx failure (Tx group) were matched for age, gender, diabetes mellitus (DM), modality and start year of PD, with 1:1 predialysis patient (nTx group). The Fine-Gray competing risk model was used to analyze mortality and technique failure.

Results

Compared to nTx, the Tx group had a lower body mass index, serum potassium, and albumin concentrations. A higher ferritin level, transferrin saturation and the number of patients with positive serology for viral hepatitis were also observed in the Tx group. In the multivariate analysis, patients of the Tx group had 4.4-times higher risk of death (p = 0.007), with infection as the main cause. Technique failure and peritonitis were similar in both groups.

Conclusion

Previous Tx is a risk factor for mortality but not for technique failure or peritonitis in incident patients on a PD program.
**Introduction**

In Brazil, between 2007 and 2017, 54,790 kidney transplantations (Tx) were performed, and in 2016, the country ranked second in the absolute number of Tx in the world [1]. Despite advances in treatment and improvements in graft survival, many transplanted patients will progress to graft loss and require dialysis. In the United States, the probability of 5-year graft failure in 2011 was 25% for deceased-donor Tx and 15% for live-donor Tx [2]. In our center, the 10-year graft failure rate was 42.3% and 26.5%, respectively [3].

Tx failure is becoming a major cause of referring patients to dialysis [4]. Some studies have shown similar mortality among patients on dialysis after renal graft loss and never transplanted [5]. Peritoneal dialysis (PD), as an option for patients with renal graft loss, has been suggested as a triggering factor for unfavorable clinical outcomes [6]. However, some studies conducted in developed countries have shown that previous Tx is not a risk factor for survival among patients on PD [7] or for the occurrence of technique failure or peritonitis [8–10].

The objective of the present study, which was conducted in a single center in Brazil, is to compare the rates of mortality, technique failure, and peritonitis in incident patients on PD coming from either Tx or pre-dialysis treatment.

**Materials and methods**

In this retrospective study, all patients who started PD after renal graft loss between January 2004 and June 2015 at the PD center of Hospital do Rim, Federal University of São Paulo, Brazil, were identified. Of the 60 patients identified, 13 were excluded due to: 1) having received more than 2 months of hemodialysis (HD) after graft failure (n = 5); 2) being on PD for less than 2 months (n = 3); 3) having more than one previous Tx (n = 3); 4) having undergone prior pancreas-kidney Tx (n = 1), and 5) being younger than 18 years old (n = 1). All patients underwent the standard training process before being admitted to the PD program.

Thus, 47 patients constituted the Tx group. These patients were matched for age, gender, the presence of diabetes mellitus (DM), PD modality [continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD)] and the year of PD initiation with 47 patients on PD coming from pre-dialysis treatment [non-Tx group (nTx)]. None of the patients in the nTx group underwent prior Tx or dialysis. Clinical outcomes were collected until June 2016 or until the patients withdrew from the dialysis program.

Clinical and laboratory data at the beginning of the PD program were collected from patients' files. The glomerular filtration rate was estimated by the CKD-EPI formula [11]. We also collected data on loss of residual renal function, being anuria considered as diuresis less than 100 mL within 24 hours. Clinical outcomes included data on death (number of deaths, time to death and cause), technique failure (number of events, time to failure and cause) and peritonitis (incidence density, etiologic agent and time to the first episode). Technique failure was defined as patient transfer to HD. The following circumstances were considered reasons for withdrawal from the study: renal function recovery, technique failure, transfer to another center, death or Tx.

The study was reviewed and approved by the Ethics Advisory Committee of the Federal University of São Paulo (approval number: 1.213.763, CAAE: 48094115.4.0000.5505) and the need for informed consent was waived. All data were anonymized to comply with the provisions of personal data protection legislation.

**Statistical analysis**

The variables were presented as the mean ± standard deviation, median (interquartile range) or percentage depending on the characteristics of the variable. The groups were compared...
using the paired Student’s t-test, Wilcoxon test, chi-square test or Fisher’s test as appropriate. The Fine-Gray model was used to investigate the factors associated with the time to death and technique failure, considering death and technique failure as competing events. Cox proportional hazards model was used to investigate factors associated with the time to the peritonitis episode. The models were fitted using simple and multiple approaches considering the variables of interest. Covariates with \( p < 0.05 \) in the univariate analysis were included in the multivariate model. The incidence density of peritonitis was estimated using a Poisson regression model considering the total follow-up time of each individual in the sample. \( P \) values \( < 0.05 \) were considered statistically significant. The analyses were performed using the statistical package R (R Core Team, 2017; Vienna, Austria), the survival (Therneau T, 2015 version 2.38, New York, United States) and cmprsk (Bob Gray, 2014, version 2.27) packages and IBM SPSS Statistics for Windows (version 20.0, Armonk, New York: IBM Corp).

Results

The demographic and laboratory data of the two groups at the beginning of treatment are shown in Table 1. The groups were similar in age, gender, year of PD initiation, PD modality and presence of DM. Compared to the nTx, the Tx group had a lower BMI, a higher number of patients with positive serology for viral hepatitis (3 with hepatitis B, 3 with hepatitis C and 1 with both), lower concentrations of potassium and albumin and higher levels of ferritin and transferrin saturation.

In the Tx group, the total time of previous renal replacement therapy (Tx + prior dialysis) was 120.5 (80–194.8) months, comprising 92.9 (49.9–165.4) months of kidney transplantation. The dialysis modalities performed before Tx were HD in 26 patients (55%), PD in 13 patients (28%) and both modalities in 5 (11%) patients. Pre-emptive Tx was performed in 3 (6%) patients. The PD follow-up was 14.8 (9.4–30.7) and 23.5 (2–21.2) months, in Tx and nTx groups, respectively (\( p = 0.42 \)). During this period, 41 (87%) patients in the Tx group received 5.0 (3.3–5.0) mg/day of prednisone for a period of 10.9 (2–21.2) months. Among these patients, 1 patient also received cyclosporine and mycophenolate sodium, which was withdrawn during the first month, and 1 patient was maintained on tacrolimus and azathioprine for 3 months. No patient in the nTx group received corticosteroids or other immunosuppressive drugs. Eight (15%) patients underwent graft nephrectomy, 1 patient, before dialysis and 7 during the PD follow-up. During the observation period, the number of patients who underwent Tx was similar [13 (28%) vs 6 (13%); Tx and nTx groups; \( p = 0.12 \)]. In addition, 1 patient (2%) within each group exhibited recovered renal function, whereas 3 patients (6%) and 1 (2%) were transferred to another center, in Tx and nTx groups, respectively.

A trend toward a higher number of deaths in the Tx group was observed [11 (23%) vs 4 (9%), \( p = 0.09 \)]. The causes of death are shown in Fig 1A. There was a trend toward a higher number of deaths due to infectious causes in the Tx group (\( p = 0.08 \)). Fig 1B shows the cumulative incidence of death in the univariate model. Considering the competitive risk with technique failure there was a trend toward a higher risk of death in the Tx group [subdistribution hazard ratio (SHR) 2.76 (95% CI 0.92–8.22), \( p = 0.07 \)]. However, in the multivariate model adjusted for age and urea, as shown in Table 2, the individuals with previous Tx had a higher risk of death [SHR = 4.4 (95% CI 1.49–13.2), \( p = 0.007 \)].

The number of patients with technique failure was similar between the groups [19 (40%) vs 18 (38%), Tx and nTx groups, respectively; \( p = 0.83 \)]. The main cause of technique failure in both groups was peritonitis (Fig 2A). In addition, Fig 2B shows that the cumulative incidence of technique failure without adjustments was similar between both groups [SHR 1.02 (95% CI 0.54–1.93), \( p = 0.94 \)]. In the multivariate model for technique failure adjusted for glucose, urea
Table 1. Demographic and laboratory characteristics at the beginning of the treatment.

|                          | Tx       | nTx      | P    |
|--------------------------|----------|----------|------|
| N                        | 47       | 47       | -    |
| Age, years               | 46.1 ±12.1 | 47 ±12.7 | 0.74 |
| Female gender            | 29 (62)  | 29 (62)  | 1.0  |
| Start, 2004–2007         | 11 (23)  | 12 (26)  | 0.68 |
| 2008–2011                | 19 (40)  | 15 (32)  |      |
| 2012–2015                | 17 (36)  | 20 (43)  |      |
| APD modality             | 40 (85)  | 40 (85)  | 1.0  |
| Diabetes mellitus        | 15 (32)  | 15 (32)  | 1.0  |
| White ethnicity          | 34 (72)  | 34 (72)  | 1.0  |
| Education, high medium   | 18 (38)  | 19 (40)  | 0.64 |
| medium low               | 10 (21)  | 15 (32)  |      |
| Etiology, Glomerulonephritis Diabetes mellitus Hypertension Unknown Other | 15 (32) | 10 (21) | 1.0  |
| 6 (13)                   | 7 (15)   | 12 (26)  |      |
| 10 (21)                  | 9 (19)   | 6 (13)   |      |
| Hypertension             | 41 (87)  | 45 (97)  | 0.27 |
| Cardiovascular disease   | 16 (34)  | 14 (30)  | 0.66 |
| Cancer                   | 3 (6)    | 4 (9)    | 0.5  |
| Viral hepatitis          | 7 (15)   | 0        | 0.01 |
| BMI kg/m²                | 23 (20.4–24.9) | 26.3 (22.8–29.9) | 0.001 |
| Presence of diuresis     | 40 (87)  | 44 (98)  | 0.11 |
| Initial PET, medium low  | 18 (56)  | 16 (42)  | 0.32 |
| medium high              | 18 (56)  | 9 (28)   |      |
| low high                 | 9 (28)   | 9 (28)   |      |
| high                     | 4 (13)   | 9 (24)   |      |
| Urea, mg/dL              | 111.3 ±37.1 | 112.6 ±37.8 | 0.86 |
| eGFR, mL/min/1.73 m²     | 6.0 (4.0–10) | 8.2 (6.0–11.1) | 0.08 |
| Sodium, mEq/L            | 139.6 ±3.6 | 139.6 ±2.5 | 0.90 |
| Potassium, mEq/L         | 4.2 ±0.6  | 4.5 ±0.5  | 0.01 |
| Glucose, mg/dL           | 82 (77–106) | 86 (78–99) | 0.70 |
| Hemoglobin, g/dL         | 10.5 ±2  | 10.8 ±1.8 | 0.45 |
| Leukocytes, cells/mm³    | 8105 ±3047 | 7583 ±2388 | 0.45 |
| Ferritin, μg/L           | 303 (163–651) | 157 (99.6–299) | 0.001 |
| Transferrin saturation, %| 33.5 (22–42) | 25 (21–33) | 0.02 |
| Phosphorus, mg/dL        | 5.8 ± 1.6 | 5.5 ±1.4  | 0.33 |
| Calcium, mmol/L          | 1.2 (1.14–1.29) | 1.25 (1.15–1.3) | 0.20 |
| iPTH, pg/dL              | 545 (192–904) | 500 (283–807) | 0.85 |
| Albumin, g/dL            | 3.4 ±0.45 | 3.8 ±0.45 | <0.001 |
| Total cholesterol, mg/dL | 196.2 ±49.2 | 197 ± 56  | 0.95 |
| HDL, mg/dL               | 40 (33–51) | 43 (35.5–52) | 0.47 |
| LDL, mg/dL               | 113.9 ±42.4 | 120.5 ±43.9 | 0.38 |
| Triglycerides, mg/dL     | 154 (110–211) | 148 (98–201) | 0.23 |

The values are described as the mean ± standard deviation, median (interquartile range) or n (%); APD = automated peritoneal dialysis; PET = peritoneal equilibration test; eGFR = glomerular filtration rate estimated by the CKD-EPI equation; iPTH = intact parathyroid hormone; LDL = low-density lipoprotein; HDL = high-density lipoprotein

https://doi.org/10.1371/journal.pone.0227870.t001
and phosphorus, as shown in Table 2, previous Tx was not associated with the occurrence of technique failure [SHR 1.14 (95% CI 0.59–2.21), \( p = 0.69 \)].

When the groups were compared, the number of patients with peritonitis was not different [29 (62%) vs 20 (43%), Tx and nTx groups, respectively; \( p = 0.63 \)]. A trend toward a higher incidence density of peritonitis was identified in the Tx group (0.59 vs 0.40 episodes/patient/year, Tx and nTx groups, respectively; \( p = 0.06 \)). The time to the first peritonitis episode was similar between the groups [9.9 (3.0–6.5) vs 7.5 (5.0–16.8) months, Tx and nTx groups, respectively; \( p = 0.73 \)]. \[ \text{Fig 3} \] shows the cumulative incidence of peritonitis, which was similar between the groups [HR 1.59 (95% CI 0.90–2.82); \( p = 0.11 \)]. In the multivariate model adjusted for albumin, prior Tx was not a risk factor for peritonitis [HR 1.41 (95% CI 0.78–2.56); \( p = 0.25 \)].

No difference was found in the microorganisms identified in the peritoneal dialysate between the two groups (\( p = 0.68 \)). Gram-positive agents were found more frequently, and among these agents, \textit{Staphylococcus aureus} had the highest incidence (Table 3).

After one year in PD program 21 and 22 patients from Tx and nTx groups, respectively, had data on diuresis recorded in their files. From these, 17 (81%) in Tx and 2 (9%) in nTx group evolved to anuria (\( p < 0.001 \)).

**Discussion**

The present study showed that patients who started PD after Tx failure presented a higher risk of death compared to those coming from pre-dialysis treatment. By contrast, the two groups did not differ regarding the occurrence of technique failure or peritonitis.

**Table 2. Multivariate analysis: Death and technique failure as competing events (Fine-Gray model).**

| Fine Gray to Death | SHR (95%CI) | \( p \) | Fine Gray to technique failure | SHR (95%CI) | \( p \) |
|--------------------|-------------|-------|-----------------------------|-------------|-------|
| Previous Transplantation | 4.44 (1.49; 13.22) | \textbf{0.007} | Previous Transplantation | 1.14 (0.59; 2.21) | 0.69 |
| Age (years) | 1.09 (1.03; 1.15) | \textbf{0.002} | Glucose (10 units) | 1.06 (1.01; 1.11) | \textbf{0.03} |
| Urea | 0.99 (0.97; 0.998) | \textbf{0.03} | Urea | 1.00 (0.997; 1.001) | 0.33 |
| | | | Phosphorus | 1.260 (1.02; 1.56) | \textbf{0.04} |

https://doi.org/10.1371/journal.pone.0227870.t002

---

Fig 1. Causes (A) and cumulative incidence (Fine-Gray model) (B) of death. Tx = group with graft failure; nTx = group coming from pre-dialysis patients; SHR = subdistribution hazard ratio.

https://doi.org/10.1371/journal.pone.0227870.g001
The impact of previous Tx on the survival of the PD population remains controversial in the literature. Similar to our findings, one study [6] reports worse survival rates among patients on PD with previous Tx, while other studies do not confirm this relationship [7–9, 12, 13].
These divergent results could be partially related to the characteristics of the studied population. Some studies did not control the presence of diabetes or even the age of the patients, which are well-known risk factors for mortality [14, 15]. Other factors such as pre-dialysis care, albumin, hemoglobin, residual diuresis and glomerular filtration rate have been associated with mortality in patients undergoing dialysis after graft loss [16]. In the present study, Tx patients had higher mortality mainly due to infectious diseases, which could be partially explained by the lower albumin levels and BMI observed in this group on the time of admission in the PD program. These findings could be a characteristic of the Tx failure phase. In fact, this period has been frequently associated with low serum albumin, elevated inflammation markers, and poor nutritional status [17], partially due to poor clinical management provided during the progressive graft loss period [18–20]. Of note, low albumin is described as a risk factor to the occurrence of peritonitis and mortality from infectious causes in PD cohorts [21, 22].

Another factor as iron overload, evidenced by higher serum ferritin and transferrin saturation, could also have contributed to the high mortality rate in the Tx group. Some studies involving HD patients with intravenous iron supplementation have shown that iron overload is associated with a higher occurrence of infectious disease [23–25]. This relationship has not yet been widely studied in PD patients. The higher mortality rate observed in the Tx group could also be related to the loss of residual renal function. In a subset of the studied population, a higher number of patients from the Tx group evolved with anuria, which can be explained by the fast reduction of immunosuppressive drugs. Studies have demonstrated that the greater loss of kidney function is related to worse survival in the PD population [26, 27]. Although the loss of residual kidney function has been more frequent in PD patients with previous Tx [28], the direct relationship between that condition and mortality in this population is not clear [29]. One could speculate why the cause of mortality in our patients was infectious, while US data from mortality in PD population point out to cardiovascular disease [2]. One hypothesis could be the characteristic of the study design, as 50% of the patients came from the Tx program. Differently from patients without previous transplant, these patients were exposed to an immunosuppressive regimen.

Regarding the technique survival, in accordance with others [10, 29], no difference was found between the groups in the present study. In contrast, Chaudhri et al. found a higher rate of technique failure in patients coming from Tx compared to never-transplanted patients [12]. Yet Benomar et al. have reported similar results, and pointed out that poor dialysis adequacy

| Table 3. Microbiological characteristics of peritonitis. |
|-----------------|-------|-------|
| Microorganism   | Tx    | nTx   |
| Gram-positive cocci | 28 (50) | 18 (47) |
| Staphylococcus aureus | 17 (30) | 10 (26) |
| Coagulase-negative | 8 (14) | 7 (18) |
| Other           | 3 (5) | 1 (3) |
| Gram-negative bacilli | 9 (16) | 5 (13) |
| Pseudomonas     | 4 (7) | 1 (3) |
| Fungi           | 1 (2) | 0 |
| Gram-positive bacilli (Corynebacterium spp.) | 0 | 1 (3) |
| Other (not identified) | 7 (13) | 5 (13) |
| Negative culture | 11 (20) | 9 (24) |

https://doi.org/10.1371/journal.pone.0227870.t003
was the main cause of technique failure [7]. Of note, in the present study, peritonitis was the main cause of technique failure in both groups.

Considering peritonitis, Chen et al. found a trend toward a lower event-free time in pediatric patients who started PD after Tx failure compared to those who were transplanted naive [30]. However, studies on the adult population showed no difference regarding peritonitis between groups [7, 9, 12]. Notably, in those studies, different immunosuppressive protocols were performed after PD initiation, making a comparison between them difficult to analyze. In the present study, a trend toward a higher incidence of peritonitis in the Tx group was found, which could be related to the use of immunosuppressive drugs by these patients.

The present study has some limitations, including the relatively small sample and the single-center retrospective design. It should also be noted that the Tx group has had a longer CKD time, and consequently, longer exposure to disease complications. However, our sample is one of the largest cohorts among single-center studies in patients with graft failure starting PD. In addition, we employed appropriate statistical analyses as a competitive risk for the main outcomes.

In conclusion, previous Tx is a risk factor for mortality but not for technique failure or peritonitis in incident patients on a PD program. Further studies with larger samples are needed and also could be of interest to investigate the outcomes of incident patients on HD program coming from Tx, to establish a better dialysis modality, PD or HD, and to better management of immunosuppressives drugs to patients after kidney allograft failure.

Supporting information
S1 Appendix. All data.
(XLS)

Author Contributions
Conceptualization: Laurisson Albuquerque da Costa, Maria Cláudia Cruz Andreoli, Aluizio Barbosa Carvalho, José Osmar Medina Pestana, Maria Eugênia Fernandes Canziani.
Data curation: Sérgio Antonio Draibe, Maria Eugênia Fernandes Canziani.
Formal analysis: Laurisson Albuquerque da Costa, Maria Cláudia Cruz Andreoli, Aluizio Barbosa Carvalho, Sérgio Antonio Draibe, José Osmar Medina Pestana, Maria Eugênia Fernandes Canziani.
Investigation: Laurisson Albuquerque da Costa, Maria Cláudia Cruz Andreoli, Aluizio Barbosa Carvalho, Sérgio Antonio Draibe, José Osmar Medina Pestana, Maria Eugênia Fernandes Canziani.
Methodology: Laurisson Albuquerque da Costa, Maria Cláudia Cruz Andreoli, Maria Eugênia Fernandes Canziani.
Project administration: Maria Cláudia Cruz Andreoli, José Osmar Medina Pestana, Maria Eugênia Fernandes Canziani.
Supervision: Maria Cláudia Cruz Andreoli, Aluizio Barbosa Carvalho, Sérgio Antonio Draibe, Maria Eugênia Fernandes Canziani.
Validation: José Osmar Medina Pestana.
Visualization: Maria Cláudia Cruz Andreoli, Sérgio Antonio Draibe, José Osmar Medina Pestana, Maria Eugênia Fernandes Canziani.
Writing – original draft: Laurisson Albuquerque da Costa, Maria Cláudia Cruz Andreoli, Aluizio Barbosa Carvalho, Maria Eugênia Fernandes Canziani.

Writing – review & editing: Laurisson Albuquerque da Costa, Maria Cláudia Cruz Andreoli, Aluizio Barbosa Carvalho, Maria Eugênia Fernandes Canziani.

References

1. Brazil. Associação Brasileira de Transplantes. Registro Brasileiro de Transplantes. Dimensionamento do Transplante no Brasil e em cada Estado (2010–2017). [Accessed on 2019 Feb 25]. Available from: http://www.abto.org.br/abtov03/Upload/file/RBT/2017/rbt-impressa-leitura-compressed.pdf.

2. United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.

3. de Castro Rodrigues Ferreira F, Cristelli MP, Paula MI, Proença H, Felipe CR, Tedesco-Silva H, et al. Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center. J Nephrol. 2013; 26(6):667–74. https://doi.org/10.1111/j.12129 PMID: 24016076

4. Molnar MZ, Ichii H, Lineen J, Foster CE, Mathe Z, Schiff J, et al. Timing of return to dialysis in patients with failing kidney transplants. Semin Dial. 2013; 26(6):667–74. PMID: 24016076

5. Rao PS, Schaubel DE, Saran R. Impact of graft failure on patient survival on dialysis: a comparison of transplant-naive and post-graft failure mortality rates. Nephrol Dial Transplant. 2005; 20(2):387–91. PMID: 15850025

6. Sasan J, Naimark D, Klassen J, Bargman JM. Late renal transplant failure: an adverse prognostic factor at initiation of peritoneal dialysis. Perit Dial Int. 2001; 21(4):405–10. PMID: 11587406

7. Benomar M, Vachey C, Lobbedez T, Henriques J, Ducloux D, Vernerey D, et al. Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF). Nephrol Dial Transplant. 2018.

8. Mujais S, Story K. Patient and technique survival on peritoneal dialysis in patients with failed renal allograft: a case-control study. Kidney Int Suppl. 2006(103):S133–7. https://doi.org/10.1038/sj.ki.5001930 PMID: 17080105

9. Duman S, Asçi G, Töz H, Özkaya M, Ertlilav M, Sezış M, et al. Patients with failed renal transplant may be suitable for peritoneal dialysis. Int Urol Nephrol. 2004; 36(2):249–52. https://doi.org/10.1023/b:urol.0000034678.84908.9b PMID: 15368705

10. Badve SV, Hawley CM, McDonald SP, Mudge DW, Rosman JB, Brown FG, et al. Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrol Dial Transplant. 2006; 21(3):776–83. https://doi.org/10.1093/ndt/gfl248 PMID: 16280374

11. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 PMID: 19414839

12. Chaudhri S, Thomas AA, Samad N, Fan SL. Peritoneal dialysis in patients with failed kidney transplant: single centre experience. Nephrology (Carlton). 2016.

13. Yang KS, Kim JI, Moon IS, Choi BS, Park CW, Yang CW, et al. The clinical outcome of end-stage renal disease patients who return to dialysis after renal allograft failure. Transplant Proc. 2013; 45(8):2949–52. https://doi.org/10.1016/j.transproceed.2013.08.080 PMID: 24157010

14. Joshi U, Guo Q, Yi C, Huang R, Li Z, Yu X, et al. Clinical outcomes in elderly patients on chronic peritoneal dialysis: a retrospective study from a single center in China. Perit Dial Int. 2014; 34(3):299–307. https://doi.org/10.3747/pdi.2012.00209 PMID: 24293663

15. Coronel F, Cigarrán S, Herrero JA. Morbidity and mortality in diabetic patients on peritoneal dialysis. Twenty-five years of experience at a single center. Nefrologia. 2010; 30(6):626–32. https://doi.org/10.3265/Nefrologia.pre2010.Jul.10553 PMID: 21113211

16. Brar A, Markell M, Stefanov DG, Timpo E, Jindal RM, Nee R, et al. Mortality after Renal Allograft Failure and Return to Dialysis. Am J Nephrol. 2017; 45(2):180–6. https://doi.org/10.1159/000455015 PMID: 28110327

17. Yelken BM, Gorgulu N, Caliskan Y, Yazici H, Turkmen A, Yildiz A, et al. Comparison of nutritional status in hemodialysis patients with and without failed renal allografts. Clin Transplant. 2010; 24(4):481–7. https://doi.org/10.1111/j.1399-0012.2009.01097.x PMID: 19786450
18. Ansell D, Udayaraj UP, Steenkamp R, Dudley CR. Chronic renal failure in kidney transplant recipients. Do they receive optimum care?: data from the UK renal registry. Am J Transplant. 2007; 7(5):1167–76. https://doi.org/10.1111/j.1600-6143.2007.01745.x PMID: 17355238

19. Kaysi S, Hadj Abdelkader M, Aniort J, Garrouste C, Philippouret C, Detex P, et al. Chronic renal failure complications and management in kidney transplanted and nontransplanted patients. Transplant Proc. 2012; 44(10):2997–3000. https://doi.org/10.1016/j.transproceed.2012.05.084 PMID: 23195913

20. Marce R, del Castillo D, Capdevilla L, Fernandez-Fresnedo G, Rodrigo E, Cantarell C, et al. Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain. Transplantation. 2009; 87(9):1340–6. https://doi.org/10.1097/TP.0b013e3181a23837 PMID: 19424034

21. Mehrotra R, Duong U, Jiwakanon S, Kovesdy CP, Moran J, Koppell JD, et al. Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis. Am J Kidney Dis. 2011; 58(3):418–28. https://doi.org/10.1053/ajkd.2011.03.018 PMID: 21601335

22. Wang Q, Bernardini J, Piraino B, Fried L. Albumin at the start of peritoneal dialysis predicts the development of peritonitis. Am J Kidney Dis. 2003; 41(3):664–9. https://doi.org/10.1053/ajkd.2003.50128 PMID: 12612991

23. Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, et al. Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol. 2014; 9(11):1930–9. https://doi.org/10.2215/CJN.03370414 PMID: 25318751

24. Zitt E, Sturm G, Kronenberg F, Neyer U, Knoll F, Lhotta K, et al. Iron supplementation and mortality in incident dialysis patients: an observational study. PLoS One. 2014; 9(12):e114144. https://doi.org/10.1371/journal.pone.0114144 PMID: 25462819

25. Ishida JH, Marafino BJ, McCulloch CE, Dainymple LS, Dudley RA, Grimes BA, et al. Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection. Clin J Am Soc Nephrol. 2015; 10(10):1799–805. https://doi.org/10.2215/CJN.00901015 PMID: 26416943

26. Bargman JM, Thorpe KE, Churchill DN, Group CPDS. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001; 12(10):2158–62. PMID: 11562415

27. Hu SL, Josti P, Kaplan M, Lefkovitz J, Poenaria D, Dworkin LD, et al. Rapid Change in Residual Renal Function Decline Is Associated with Lower Survival and Worse Residual Renal Function Preservation in Peritoneal Dialysis Patients. Perit Dial Int. 2017; 37(4):477–81. https://doi.org/10.3747/periintl.2016.00211 PMID: 2867514

28. Madar H, Korzets A, Ori Y, Herman M, Levy-Drummer RS, Gafter U, et al. Residual renal function in peritoneal dialysis after renal transplant failure. Perit Dial Int. 2010; 30(4):470–4. https://doi.org/10.3747/periintl.2009.00168 PMID: 20628109

29. Davies SJ. Peritoneal dialysis in the patient with a failing renal allograft. Perit Dial Int. 2001; 21 Suppl 3: S280–4.

30. Chen A, Martz K, Rao PS. Does allograft failure impact infection risk on peritoneal dialysis: a North American Pediatric Renal Trials and Collaborative Studies Study. Clin J Am Soc Nephrol. 2012; 7(1):153–7. https://doi.org/10.2215/CJN.03160411 PMID: 22246284